By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Pharma R & D Spending is Down
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Pharma R & D Spending is Down
BusinessHealth Reform

Pharma R & D Spending is Down

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

And that’s probably bad news. Here is Megan McArdle, writing in The Atlantic:

For the first time ever last year, the global drug industry cut its R&D spending.  The trend is expected to continue, at least in the near term.

And that’s probably bad news. Here is Megan McArdle, writing in The Atlantic:

For the first time ever last year, the global drug industry cut its R&D spending.  The trend is expected to continue, at least in the near term.

More Read

hospital recruitment
Hospital Recruitment Tweaks to Help You Hire More Qualified Applicants
Dr. Ryan Shelton Reveals 9 Data-Driven Tips for Optimal Health
ACA Rollout Hits Some Massachusetts Businesses Harder Than Expected
Healthcare’s Interoperability Problem: A Q and A with HIMSS CEO
Bariatric Surgery Linked to Reduced Risk of Cardiovascular Death

You might initially think that this is good news for cost control–the expensive brand name drugs will all go generic, and we’ll save a bunch of money on prescription drugs.  And indeed, this is absolutely true.  But this will have repercussions for other areas of health care, and those repercussions are not good.  While some drugs are simply an added expense (think chemotherapy prolonging the lives of people who would otherwise have died sooner), many of the real blockbusters substitute for labor-intensive treatment.  Statins instead of cardiac catheterizations or coronary bypasses.  Avandia instead of amputations.  Hydro-chlorothiazide instead of nursing home care for your massive stroke.

We’ll still have all those drugs, of course.  But with less R&D, we’ll presumably see fewer pharmaceutical substitutes for the expensive conditions we still spend a lot of money treating, like Alzheimer’s. Which means that health care expenses might actually rise faster than we expect.

   

TAGGED:healthcare businesshealthcare reformpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

uv protection in winter
Winter Sun Safety: Why UV Protection Matters Year-Round
Health
October 29, 2025
Nurse Scheduling Software
Evaluating 7 Best Nurse Scheduling Software
Nursing Technology
October 28, 2025
contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025

You Might also Like

InVivo Therapeutics Treats the Spinal Cord Itself, A Novel Technology

August 16, 2011
affordable care act
Health ReformMedical EducationPolicy & LawPublic Health

How Is President Obama Doing on His Campaign Promises?

May 7, 2013

Good Flavors and Obesity

December 2, 2011
pfizer and clinical data transparency
BusinessMedical RecordsPolicy & Law

Pfizer to Expand Clinical Trial Data Access, Takes Step Toward Transparency

December 6, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?